Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Core Insights - The company has disclosed that the run rate for mavacamten in hypertrophic cardiomyopathy (HCM) has exceeded $1 billion, indicating a substantial market potential for this treatment [1] - The growth of the HCM market is supported by the introduction of additional agents, which is expected to further expand the market [1] - The current limitation in market penetration for mavacamten is primarily due to its utilization being concentrated in specialized centers, with challenges in reaching community cardiologists [1]